Sangui Biotech International, Inc. (SGBI) Research

Sangui Biotech International, Inc., through its subsidiary Sangui BioTech GmbH, specializes in creating artificial oxygen carriers derived from hemoglobin. These innovative products are utilized as blood supplements, blood volume replacements, and various related formulations. The company's oxygen carriers are vital for delivering oxygen to humans experiencing acute or chronic oxygen deprivation due to conditions like blocked arteries, anemia, or blood loss, as well as for managing chronic wounds. Their product line also includes nano-formulations designed for skin regeneration, enhancing moisture and elasticity. Furthermore, they provide Chitoskin wound pads to aid in healing and Hemospray, a medical-grade spray specifically formulated for treating persistent wounds. The wound spray products, marketed under the Granulox brand, are primarily distributed in Europe and Mexico, while their cosmetic items are available through an online store. Established in 1995, Sangui Biotech International, Inc. is based in Hamburg, Germany.

Market snapshot

Symbol
SGBI
Price
$0.00
Day change
0.00%
Market cap
$42.0K
P/E ratio
0.34x
52-week range
0.0002-0.0015
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Aleafia Health Inc. (ALEAF)
  • Wholehealth Products, Inc. (GWPC)
  • Mojave Brands Inc. (HHPHF)
  • HTC Purenergy Inc. (HTPRF)
  • NMC Health plc (NMHLY)
  • Ontrak, Inc. (OTRKQ)
  • Revium Recovery Inc. (RVRC)
  • Skylight Health Group Inc. (SLHGF)

Recent insider activity

  • Striepe Thomas — trade (0 shares) on 2022-06-30
  • Schmelz Hubertus — trade (0 shares) on 2022-06-30
  • Schmelz Hubertus — S-Sale (1200000 shares) on 2021-10-13
  • Schmelz Hubertus — trade (0 shares) on 2021-06-30
  • Striepe Thomas — trade (0 shares) on 2021-06-30

Open Sangui Biotech International, Inc. (SGBI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.